Navigation Links
Cornell makes cancer vaccine for clinical use
Date:8/20/2009

ITHACA, N.Y. The Bioproduction Facility at Cornell University has produced the first batch of NY-ESO-1 recombinant proteina cancer vaccinethat will be used in clinical trials for patients facing either ovarian cancer or melanoma. The facility was developed as a partnership between The Ludwig Institute for Cancer Research and Cornell University.

The melanoma trial is being conducted at New York University Medical Center, while the ovarian cancer vaccine trial is being conducted at the Roswell Park Cancer Institute in Buffalo, N.Y. The trials are assessing the safety and the anti-tumor immune response of the NY-ESO-1-specific therapeutic cancer vaccine alone and in combination with other agents, according to the Cancer Research Institute (CRI), an organization that has recently given $450,000 to Cornell to support vaccine production at the Facility.

The goal of these trials is to maximize the body's immune response to the NY-ESO-1 protein. "Making NY-ESO-1 available for these clinical trials allows investigators to test ways to develop effective cancer vaccines," says Carl A. Batt, Cornell Liberty Hyde Bailey Professor of Food Science and director of the Bioproduction Facility.

Batt says: "This vaccine is not intended to prevent cancer, but one that will stimulate the body to fight an existing tumor. The challenge is that the vaccine is made from moleculesproteinsthat are found in our own bodies and do not normally induce strong immune responses. So part of this trial is to understand how to make the body react to these molecules and attack the cancer."

In 1997, Lloyd J. Old, then-scientific director of the Ludwig Institute for Cancer Research Ltd (LICR), and Yao-Tseng Chen, surgical and molecular pathologist at the Weill Cornell Medical College in New York City, discovered the NY-ESO-1 cancer/testis antigen, which has been found to be expressed by many different cancer types. NY-ESO-1 has been the central focus of the CRI/LICR Cancer Vaccine Collaborative, a global network of laboratory and clinical scientists devoted to the development of cancer vaccines. The immune-boosting effect of NY-ESO-1 vaccines has been studied in more than 40 early phase, single-variable clinical trials. The Cornell NY-ESO-1 protein will be used in other Cancer Vaccine Collaborative clinical trials around the world.

Nasser Altorki, a professor of cardiothoracic surgery and the director of the Division of Thoracic Surgery at New York Presbyterian-Weill Cornell Medical Center, performed some of the earliest NY-ESO-1 vaccine trials.

When the Bioproduction Facility opened in 2002, Old, director of the Ludwig Institute Branch of Human Cancer Immunology at Memorial Sloan-Kettering Cancer Center in New York, and Hunter R. Rawlings III, then-president of Cornell University, challenged the traditional view that making therapeutic cancer products for human testing is the sole territory of pharmaceutical and biotechnology companies. This project has helped show that academic institutions can substantially participate in drug development.

The Ludwig Institute for Cancer Research provided the initial $2 million to create the Bioproduction Facility, and continues to fund its ongoing operations with recent additional support from The Atlantic Philanthropies. Since then, professional staff and Cornell graduate and undergraduate students have operated the facility. This Good Manufacturing Practice (GMP) facility was created behind the nearly century-old faade of Stocking Hall (in which Cornell students once took dairy-science classes). It consists of a series of clean rooms, where particulates even smaller than bacteria are filtered. Strict GMP regulations, administered by the U.S. Food and Drug Administration, are used by pharmaceutical, medical device and food manufacturers as they produce and test products.

The effort to bring the laboratory and production unit from idea to reality was led by Batt, Old, and Gerd Ritter, associate director of the LICR New York Branch. Initial discussions to create a facility began between Cornell and LICR in 1998. By the following year, Cornell had signed an agreement with LICR to create it.

Regarding this protein batch now going into clinical trial, Batt says, "We don't expect miracles, but the current array of surgical, radiation and chemotherapy options are not going to eliminate all types of cancers. What these cancer vaccines offer is another tool to help combat cancer, which can be used in conjunction with other existing therapeutic options. Also, bringing together our cancer vaccine development efforts in Ithaca with the clinical research programs of Drs. Nasser Altorki, Yao Chen, and their colleagues at the university's medical school in New York City represents an excellent model for integrating activities at the two campuses."


'/>"/>

Contact: Blaine Friedlander
bpf2@cornell.edu
607-254-8093
Cornell University
Source:Eurekalert

Related medicine news :

1. NIH selects Weill Cornell Medical College to lead new NYC translational research collaboration
2. Healthy restaurants help make us fat, says a new Cornell study
3. The latest about male infertility and testosterone from NewYork-Presbyterian/Weill Cornell
4. White House awards Weill Cornells Bruce McCandliss highest honor for early career scientists
5. Weill Cornell receives $2.4 million in grants from Gates Foundation to fight tuberculosis
6. NewYork-Presbyterian/Weill Cornell creates world-class cancer center
7. By color-coding atoms, new Cornell electron microscope promises big advance in materials analysis
8. $50 million gift to NewYork-Presbyterian Hospital/Weill Cornell Medical Center
9. Weill Cornell team identifies potential new drug targets against hormone-dependent breast cancer
10. Weill Cornell receives funding to study creation of new elder abuse center
11. Weill Cornell Medical College Announces First Commencement of Its New Medical School Graduates in Doha, Qatar, May 8, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... ... ... Lice Troopers, the lice removal company based in South Florida, has seen ... season. , “It happens every year around this time,” says owner, Arie Harel. ... is the head-to-head gateway that lice need to spread.” , As children return to ...
(Date:1/20/2017)... FL (PRWEB) , ... January 20, 2017 , ... International ... of nutritional and bodybuilding supplements, announced it attended the January ECRM trade show in ... bodybuilder and nutritional scientist who was determined to create a line of products that ...
(Date:1/20/2017)... ... , ... "TransFlare 4K Mystique comes with 44 colorful mysterious transitions that are ... Austin - CEO of Pixel Film Studios. , TransFlare 4K Mystique contains 44 ... flare and light leak transitions have a very high-dynamic range for super smooth falloff. ...
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... “Mary Magdalene: ... the mysterious life of the woman who witnessed Jesus Christ firsthand. “Mary Magdalene: Grace ... denizen, who spent her career as an educator interacting with countless women who had ...
(Date:1/20/2017)... ... 2017 , ... “Code Word: Chocolate Biscuit”: a biographical account following a man who went on ... of published author, Marlyn Ivey, born in Lynn Haven, Florida and at the age of ... 19 years of age, he joined the Navy and got married right out of boot ...
Breaking Medicine News(10 mins):
(Date:1/21/2017)... According to a new market research report "Life Science Analytics ... (Software, Service), Delivery (On premise, Cloud), End user (Pharmaceutical, Biotechnology, Medical ... is expected to reach USD 24.73 Billion by 2021 from USD ... forecast period. Continue Reading ... ...
(Date:1/20/2017)... -- Research and Markets has announced the addition ... BMP, BUN Creatinine, Electrolyte Testing, HbA1c Testing, Comprehensive Metabolic Panel, Liver ... - 2024" report to their offering. ... The global clinical laboratory testing market ... Introduction of innovative solutions on the grounds of maximum efficiency and ...
(Date:1/20/2017)... BUFFALO, N.Y. , Jan. 20, 2017 /PRNewswire/ ... health programs, has announced the launch of an ... to new guidelines on opioids and helps stem ... Opioids are often prescribed to treat chronic non-cancer ... disease) despite serious risks and lack of evidence ...
Breaking Medicine Technology: